NCT02772627View on ClinicalTrials.gov

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

December 31, 2001

Study Completion Date

December 31, 2001

Conditions
Parkinson's Disease
Interventions
DRUG

Nebicapone

Nebicapone 100 mg tablets; oral route.

DRUG

Placebo

Placebo tablets; oral route.

Trial Locations (1)

4745-457

Human Pharmacology Unit - BIAL - Portela & Ca, S.A., S. Mamede Do Coronado

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02772627 - Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 | Biotech Hunter | Biotech Hunter